NL

Netherlands

NL

Europe

Regulatory Overview

Netherlands is regulated by the CBG-MEB (College ter Beoordeling van Geneesmiddelen). The country has 2 documented regulatory pathways for accessing unapproved or unlicensed medicines, covering named patient programs, compassionate use schemes, and special access arrangements.

Regulatory Authority

CBG-MEB (College ter Beoordeling van Geneesmiddelen)

Regulatory Pathways (2)

Dutch named patient supply allowing pharmacists to prepare or import unlicensed medicines for individual named patients under physician prescription.

Application Form: CBG-MEB Named Patient Form
Legal Basis: Geneesmiddelenwet (Netherlands Medicines Act)
Eligibility: Serious or life-threatening condition with no locally registered alternative
Reference: CBG-MEB Named Patient Guidance

EMA Article 83 compassionate use framework allowing access to unauthorised medicinal products for groups of patients with a chronically or seriously debilitating or life-threatening disease in Netherlands.

Application Form: National compassionate use form
Legal Basis: Regulated under EU Directive 2001/83/EC
Eligibility: Serious or life-threatening condition with no locally registered alternative
Reference: EMA Article 83 Compassionate Use

Drugs Available (26)

DrugAccess RouteStatusLead Time
naproxen
mitapivat
ruxolitinib
etanercept
mannose
testosterone
Dexrazoxane
melatonin
Total Parenteral Nutrition
Betaine anhydrous
oxybutynin
sirolimus
idebenone
Carboplatin
estradiol
atidarsagene autotemcel
Laser photocoagulation therapy
N-acetylcysteine
Occupational and Physical Therapy Support
Pamidronate
ezetimibe
atorvastatin
Growth Hormone
copper histidinate
cornstarch
mannose-1-phosphate
NL
Netherlands
ISO CodeNL
RegionEurope
Regulatory AuthorityCBG-MEB (College ter Beoordeling van Geneesmiddelen)
Pathways2 documented
Drugs Available26 drug(s)